AWM
ABUS icon

Apollon Wealth Management’s Arbutus Biopharma ABUS Stock Holding History

Apollon Wealth Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,725
Closed -$35.5K – 941
2023
Q1 		$35.5K Buy
11,725
+125
+1% +$353 ﹤0.01% 850
2022
Q4 		$27K Hold
11,600
– – ﹤0.01% 836
2022
Q3 		$22K Hold
11,600
– – ﹤0.01% 794
2022
Q2 		$31K Buy
+11,600
New +$29.7K ﹤0.01% 734

Other funds holding ABUS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Apollon Wealth Management's ABUS Position: Q2 2023 in Review

Apollon Wealth Management sold out of Arbutus Biopharma (ABUS) in Q2 2023, closing a stake of 11,725 shares — an estimated $35.5K sold.

Apollon Wealth Management first reported a position in ABUS in Q2 2022 and held it in 4 quarters. The position peaked at $35.5K in Q1 2023. 111 funds tracked by Wall St. Rank hold ABUS as of Q2 2023.

  • Apollon Wealth Management reported no remaining Arbutus Biopharma position as of Q2 2023 after selling out during the quarter.
  • Apollon Wealth Management sold 11,725 Arbutus Biopharma shares in Q2 2023, an estimated $35.5K.
  • Apollon Wealth Management first reported a position in Arbutus Biopharma in Q2 2022 and held it in 4 quarters.
  • Apollon Wealth Management's Arbutus Biopharma position peaked at $35.5K in Q1 2023.
  • 111 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2023.

Based on Apollon Wealth Management's 13F filing for Q2 2023, filed 4 Aug 2023.